menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

MET Inhibition in Metastatic NSCLC “In the Spotlight”

Join us as we discuss the significant role of MET expression in NSCLC. This re-broadcast of the Live Event at WCLC 2023, designed for medical oncologists and pathologists, will explore strategies to apply the latest clinical trial data into practice and improve multidisciplinary collaboration. Sign up now to develop the skills needed to adopt MET inhibitors in potential future indications.

Live Broadcast
1.00 available credits
Information
September 27, 2023
18:00 - 19:00 CEST
Online
ReachMD Healthcare Image
Please select your preferred calendar provider to add MET Inhibition in Metastatic NSCLC “In the Spotlight” to your calendar:
Details
Presenters
Comments
  • Overview

    Join us for this re-broadcast of the Live Event at WCLC 2023 as we discuss incorporating MET inhibitors into critical treatment decisions. It will cover evidence-based and consensus-guided recommendations and the latest data from completed and ongoing clinical trials demonstrating the application of MET inhibitors in the treatment of NSCLC. Our goals for this symposium are to further the adoption of best practices for patient selection and molecular profiling and explore global regulatory approvals and data that indicate how MET inhibitors could overcome aberrant EGFR TKI treatment resistance.

    Please see below for when the Live Broadcast will begin in your time zone:

    • 6 PM CEST
    • 12 PM ET
    • 9 AM PT

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty
    Paul K. Paik, MD

    Clinical Director, Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, NY, United States

    Consulting Fees: ACE Oncology, Crown Bioscience Inc., EMD Serono Inc., Medscape, Mirati Therapeutics, Novartis, PER Events, LLC, Research To Practice, Takeda Pharmaceuticals

    D. Ross Camidge, MD, PhD
    Director, Thoracic Oncology
    University of Colorado
    Aurora, CO, United States

    Consulting Fees: AbbVie, Anheart, Beigene, Eli Lilly, Imagene, Immunocore, Janssen, Mirati, Prelude, Seattle Genetics, Valence
    Contracted Research: AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem

    Keith Kerr, BSc, MB ChB
    Department of Pathology
    Aberdeen University School of Medicine & Aberdeen Royal Infirmary
    Aberdeen, UK

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Recognize the importance of testing for MET gene aberrations
    • Identify effective testing modalities for biomarker assessment, including the benefits of liquid biopsy
    • Summarize recent trial results and recognize how these affect current clinical practice
    • Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance
    • Understand guideline updates to treating patients with MET+ NSCLC
    • Implement treatment planning strategies that account for patient preferences and improve adherence
  • Target Audience

    This activity is designed to meet the educational needs of  medical oncologists, pathologists, pulmonologists, and healthcare providers who manage patients with NSCLC. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    Join us for this re-broadcast of the Live Event at WCLC 2023 as we discuss incorporating MET inhibitors into critical treatment decisions. It will cover evidence-based and consensus-guided recommendations and the latest data from completed and ongoing clinical trials demonstrating the application of MET inhibitors in the treatment of NSCLC. Our goals for this symposium are to further the adoption of best practices for patient selection and molecular profiling and explore global regulatory approvals and data that indicate how MET inhibitors could overcome aberrant EGFR TKI treatment resistance.

    Please see below for when the Live Broadcast will begin in your time zone:

    • 6 PM CEST
    • 12 PM ET
    • 9 AM PT

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty
    Paul K. Paik, MD

    Clinical Director, Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, NY, United States

    Consulting Fees: ACE Oncology, Crown Bioscience Inc., EMD Serono Inc., Medscape, Mirati Therapeutics, Novartis, PER Events, LLC, Research To Practice, Takeda Pharmaceuticals

    D. Ross Camidge, MD, PhD
    Director, Thoracic Oncology
    University of Colorado
    Aurora, CO, United States

    Consulting Fees: AbbVie, Anheart, Beigene, Eli Lilly, Imagene, Immunocore, Janssen, Mirati, Prelude, Seattle Genetics, Valence
    Contracted Research: AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem

    Keith Kerr, BSc, MB ChB
    Department of Pathology
    Aberdeen University School of Medicine & Aberdeen Royal Infirmary
    Aberdeen, UK

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Recognize the importance of testing for MET gene aberrations
    • Identify effective testing modalities for biomarker assessment, including the benefits of liquid biopsy
    • Summarize recent trial results and recognize how these affect current clinical practice
    • Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance
    • Understand guideline updates to treating patients with MET+ NSCLC
    • Implement treatment planning strategies that account for patient preferences and improve adherence
  • Target Audience

    This activity is designed to meet the educational needs of  medical oncologists, pathologists, pulmonologists, and healthcare providers who manage patients with NSCLC. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Schedule22 Jul 2024